The keynote panel, taking place at Genesis on 10 December at 1 Wimpole Street, London will explore the above question; What do you think should feature in the conversation? As the final preparations take shape, themes include:
Perceived progress in unlocking domestic institutional capital (such as pension funds and insurance pools) to support later-stage (Series B and beyond) rounds, thus reducing the reliance on overseas venture capital that often forces early cross-border buyouts.
The potential for creative commercial structures such as co-development partnerships, regional…
The keynote panel, taking place at Genesis on 10 December at 1 Wimpole Street, London will explore the above question; What do you think should feature in the conversation? As the final preparations take shape, themes include:
Breakthroughs beyond traditional small molecules and standard biologics, such as advanced RNA therapeutics (SymphoRNA), spatial genomics, and three-dimensional genome architecture (Nucleome Therapeutics).
Exploring how targeting previously "undruggable" pathways or cellular mechanisms (such as aging/longevity biology via LinkGevity or targeted protein…
New RNA-based NGS panel helps to detect, analyse and track high-impact AML-associated fusion events across multiple timepoints.
Oxford, UK, October 2026.
OGT, a leading global provider of genomic research and diagnostic solutions, today announced the launch of the SureSeq™ myPanel Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukaemia (AML). This panel is now available publicly for customers to purchase and implement in their own workflows.
Genomic AML workflows traditionally cover only part of the genomic…
Celea has now contracted Qureight as the end-to-end imaging CRO for the phase 3 SURPASS-IPF trial, including Fibr8™ and four additional AI imaging models
Joint poster at CHEST 2026 presents analysis completed as part of Qureight’s work on Celea’s phase 2b ELEVATE-IPF trial, comparing enrolled patients’ baseline fibrosis severity with the PROFILE cohort, illustrating the approach behind Qureight’s Enrolled Cohort Reports
Cambridge, UK, 20 October 2026 – Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and…
Stevenage, UK, 21 October 2026 - NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.
NRG5051 is an orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP) that acts through a novel NLRX1-mediated mechanism of action.
NRG has successfully…
15 Oct 2026Graham Hewson has been appointed as Chief Business Officer of the Royal Veterinary College (RVC) and Chief Executive Officer of the London Bioscience Innovation Centre (LBIC).
The Chief Business Officer role at the RVC has been created to strengthen the RVC’s commercial impact by helping to take the RVC’s research into industry and supporting the growth of bioscience businesses that draw on its facilities and expertise. There are many synergies between this role and that of the Chief Executive Officer at LBIC, whose role is to significantly build and support the life sciences…
Sandwich, UK — 13 October 2026: Discovery Park, Kent’s business park for science and technology companies, today welcomed two climate-tech companies to its innovation campus. Anthera Remediation Technologies, tackling 'forever chemicals' in water and soil, and Colliding Materials, building plastic compounding technology for sustainable energy systems, have now moved into new laboratory spaces in Sandwich, Kent.
Anthera Remediation Technologies (A.R.T) is focused on the removal and breakdown of PFAS from the environment. These ‘forever chemicals’ are used in many household…
One Nucleus, SLAS, and ELRIG will connect their communities through cross-event networking and partnering opportunities during London Bio-Innovation Week, taking place 7th - 11th December, 2026
One Nucleus’ Genesis conference partnering app, used by ~400 attendees in 2025, open to all
Initiative to encourage knowledge exchange, new connections and collaborations across the science and business of London’s life science ecosystem
London, UK, 14 October 2026: One Nucleus, The Society for Laboratory Automation and Screening (SLAS), and ELRIG today announced…
AMX-883, Amphista’s first asset to enter the clinic, is a potent, selective, orally bioavailable DCAF16-mediated BRD9 degrader targeting acute myeloid leukemia (AML)
The first-in-human ‘BRAMLIE’ (BR(D9) AML Interventional Evaluation) trial will assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk myelodysplastic syndrome (MDS)
AMX-883 demonstrates karyotype-independent pro-differentiation activity pre-clinically, with trial enrolling patients regardless of mutational status
Cambridge, UK, 12 October 2026: Amphista…
With plenty happening across the life sciences sector, there’s always an opportunity to keep learning, build new skills and stay connected. We’ve brought together our latest learning opportunities, designed to support professionals at every career stage, alongside our popular in-house training, offering practical and relevant learning tailored to the needs of teams across academia and industry. ________________________________________________
Upcoming Featured Opportunities
20 October 2026 | Enabling Membrane Protein CryoEM, and beyond, with Polymer Nanodiscs: A TRPML3 Case Study22…